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NEW IN 2017: UPDATE OF POLISH FORUM FOR 
PREVENTION GUIDELINES ON SMOKING
1. New data on epidemiology of smoking in the Polish 
population
2. New system of cardiovascular (CV) risk assessment for 
the population of Poland
3. New data on efficacy of pharmacological treatment
4. New data and guidelines on electronic cigarettes
1. HARMFULNESS
Smoking is one of the key factors responsible for development 
of CV, pulmonary, and digestive system diseases as well as 
a number of cancers. Smoking is responsible for 50% of all 
avoidable deaths in smokers, half of these due to CV disease, 
and lifetime smokers have a 50% probability of dying due to 
smoking. The smoking-related risk is dose dependent: smok-
ing even a few cigarettes daily is related to increased CV risk 
by 50%. A lifetime smoker on average will lose 10 years of 
life [1, 2].
2. PREVALENCE
About 8 million Poles (aged ≥ 15 years) smoke every day 
(24%). The prevalence in men is 31% and in women 18% [3]. 
Although the smoking rate has decreased substantially since 
the early eighties it is still higher compared to Western Eu-
ropean countries. The Polish average smoker smokes more 
cigarettes daily compared to the mean in the European Union 
(16 vs. 14). Smoking among children and adolescents remains 
a major problem. 
3. PASSIVE SMOKING
The health consequences of passive smoking are qualitatively 
similar to the effects of active smoking. In Poland, as many 
as 39% of adults are exposed to tobacco smoke at home 
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(22% among non-smokers) and 11% at work, including 8% 
of non-smoking women and 13% of non-smoking men [3]. 
About 25% of Poles are exposed to second-hand smoke at 
bus or tram stops. It is estimated that almost 3 million children 
in Poland are passive smokers. It is also estimated that about 
20% of pregnant women are exposed to second-hand smoke 
at home. Therefore, it is necessary to increase the protection 
of non-smokers from the harmful effects of tobacco smoke. 
4. SMOKING AND CARDIOVASCULAR DISEASES 
Smoking tobacco:
 — carries a particularly high risk for patients with other risk 
factors, such as: hypertension, dyslipidaemia, diabetes, 
obesity, sedentary lifestyle, or positive family history of 
premature CV disease;
 — adversely affects blood vessels, damaging vascular en-
dothelium and impacting vascular homeostasis;
 — increases inflammation, activates platelets and induces 
platelet aggregation, increases the expression of tissue 
factor, and impairs fibrinolysis; however. 
Cardiovascular risk decreases by half during the first year 
after smoking cessation. Subsequently it decreases gradually 
and after 15–20 years gets close to the level of never smokers. 
5. EXPOSURE ASSESSMENT,  
THE DEGREE OF DEPENDENCE,  
AND MOTIVATION TO QUIT SMOKING 
The assessment of exposure to tobacco smoke is made on 
the basis of an interview (small cost, subjective nature), which 
can be carried out using a questionnaire, and measurement 
of biomarkers (higher cost, objective measurement). Among 
others carbon monoxide in exhaled air, carboxyhaemoglobin 
in the blood, cotinine, nicotine, or thiocyanate in selected 
body fluids can be measured. 
In assessing the degree of tobacco dependence the 
Fageström test is useful. It helps to differentiate smokers in 
whom physical dependence is less important, requiring mainly 
behavioural support, from smokers with primarily severe 
biologically dependence. The latter patients need intensive 
pharmacotherapy for effective smoking cessation. Depending 
on the number of points scored the addiction may be classified 
as: low (0–2 points), low to moderate (3–4 points), moderate 
(5–6 points), or high (≥ 7 points). 
Motivation is the most important factor determining 
the success of any smoking cessation attempt. Those without 
strong motivation to quit smoking frequently return to it. 
Assessment of the degree of determination of the patient 
to make the effort required to process difficult behavioural 
changes (especially in the case of a behavioural addiction), 
and tuning of the organism to function in the absence of 
nicotine (in the case of a significant component of physical 
addiction) is essential. Although CV risk does not influence 
the treatment of smoking dependence it can be used to fur-
ther motivate the patient [4–6]. In the Polish population the 
Pol-SCORE 2015 system should be used (also for the heart 
age estimation) [7, 8]. 
6. GOAL OF THERAPY
The aim of the treatment is complete smoking cessation. 
The success of therapy is defined as non-smoking for at least 
six months. However, many people who have managed to 
achieve this goal eventually return to smoking.
7. GENERAL STRATEGY OF  
TOBACCO DEPENDENCE TREATMENT
Each patient must be made aware that addiction to tobacco is 
a disease that can and should be treated. In routine practice 
the “Five As” counselling strategy should be followed [1, 4–6]:
 — Ask — systematically identify all tobacco users at eve-
ry opportunity;
 — Advise — strongly urge all tobacco users to quit;
 — Assess — determine the degree of addiction and readi-
ness to quit;
 — Assist — agree on a smoking cessation strategy, including 
setting a quit date. Aid the patient in quitting (provide 
counselling-style support and medication);
 — Arrange — ensure follow-up contact.
8. NON-PHARMACOLOGICAL TREATMENT
Medical intervention may be limited to brief counselling 
when directed, mainly to those smoking patients who do 
not yet take into account smoking cessation. Although the 
six-month effectiveness of short medical advice is estimated 
to be 2–3%, if every doctor in Poland gave this advice to all 
his/her smoking patients about 100,000 persons would stop 
smoking in Poland yearly [4, 6]. 
Every smoking patient should be advised to stop smok-
ing during each visit in the doctor’s office. Medical risks 
related to smoking, as well as medical and personal benefits 
of breaking the addiction, should always be underlined. 
Patients should be informed about much more effective 
smoking cessation attempts if they are supported by phar-
macological or behavioural therapy. The physician should 
remember: the more intense intervention, the greater the 
chance of smoking cessation. Interventions involving peri-
odic telephone contact, providing practical guidelines for 
behaviour in the period of cessation, and providing social 
support are especially effective.
9. PHARMACOLOGICAL TREATMENT
Pharmacotherapy tobacco dependence should be seen in 
the same way as the pharmacological treatment of other risk 
factors. Available data indicate that drug treatment of tobacco 
dependence in Poland is used too rarely. Treatment of tobacco 
dependence is one of the most cost-effective methods in 
modern medicine, so it seems reasonable to introduce a partial 
reimbursement for drugs used for the treatment of tobacco 
dependence [4–6].
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Pharmacotherapy should be offered to anyone planning 
to stop smoking, especially those with severe dependence 
or complications of smoking (e.g. coronary artery disease, 
chronic obstructive pulmonary disease) [1, 4–6]. 
Pharmacological treatment of tobacco dependence syn-
drome may consist of a nicotine replacement therapy (NRT), 
bupropion, cytisine, or varenicline [1, 4–6, 9].
Nicotine replacement therapy may take the form of 
patches, gums, lozenges, sublingual tablets, inhalers, etc. All 
available forms of NRT are effective and relatively safe. Com-
bined NRT (patches + NRT in a form that provides a rapid 
increase in the level of blood nicotine, e.g. gums, inhalers) 
is more effective than NRT in monotherapy, especially in 
patients with severe addiction or in those who failed to stop 
smoking. NRT is available in Poland without a prescription. 
Other drugs registered in Poland include: bupropion, cyti-
sine, and varenicline. Of these, cytisine is available without 
a prescription. Cytisine may be a useful alternative to more 
expensive drugs. The most effective method is a combination 
of pharmacological treatment with behavioural intervention.
10. ELECTRONIC CIGARETTES
Currently, about 3% of adults use electronic cigarettes in 
Poland [3]. Although they are less harmful than traditional 
tobacco products the public should not be encouraged to use 
them because there is no evidence that they are more effective 
than traditional methods of tobacco dependence treatment 
and due to the risk of initiation of smoking (especially in 
adolescents and young adults). People who smoke traditional 
cigarettes and intend to use electronic cigarettes as a means 
of tobacco dependence treatment should be informed of 
the relatively small evidence of their effectiveness and lack 
of certainty as to their full safety. At the same time, patients 
should be encouraged to use methods that are proven to be 
effective [1, 10, 11]. 
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